Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 9/20 | 0.44 |
| ▸ | GGPS1 | O95749 | 7/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL175908 | 0.98 | FDPS (0.42) | FDPSGGPS1SMPD1PLA2G2CTP53 | |
| Choline SCHEMBL28126923 | 0.86 | PSMD14 (0.38) | FDPSGGPS1LMNA | |
| SCHEMBL4566609 | 0.84 | FDPS (0.43) | FDPSGGPS1SMPD1 | |
| SCHEMBL1890334 | 0.76 | LMNA (0.41) | FDPSGGPS1LMNATP53CYP1A2 | |
| SCHEMBL18863212 | 0.76 | LMNA (0.41) | FDPSGGPS1LMNATP53CYP1A2 | |
| SCHEMBL2226505 | 0.76 | LMNA (0.41) | FDPSGGPS1LMNATP53CYP1A2 | |
| SCHEMBL7530555 | 0.76 | LMNA (0.41) | FDPSGGPS1LMNATP53CYP1A2 | |
| SCHEMBL25815 | 0.76 | LMNA (0.41) | FDPSGGPS1LMNATP53CYP1A2 | |
| SCHEMBL10910541 | 0.76 | LMNA (0.41) | FDPSGGPS1LMNATP53CYP1A2 | |
| SCHEMBL136611 | 0.76 | LMNA (0.41) | FDPSGGPS1LMNATP53CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3229811-B1 | PREVENTION AND TREATMENT OF INFLAMMATORY CONDITIONS | GRI BIO INC (US) | 2021-02-24 | — | — | EP | disclosed |
| CN-104363894-B | For treating arthralgia or the vesicle formation of mobility's reduction | 斯昆申技术控股有限责任公司 | 2016-11-23 | — | — | CN | disclosed |
| CN-102770162-B | Vesicle formation | 靶向递送技术有限公司 | 2016-09-28 | — | — | CN | disclosed |
| CN-105434354-A | Formulations for the treatment of deep tissue pain | SEQUESSOME TECH HOLDINGS LTD | 2016-03-30 | — | — | CN | disclosed |
| CN-105434329-A | Preparation for treating pain of deep tissues | SEQUESSOME TECH HOLDINGS LTD | 2016-03-30 | — | — | CN | disclosed |
| CN-105434353-A | Formulations for the treatment of deep tissue pain | SHENSIKUN TECH CO LTD | 2016-03-30 | — | — | CN | disclosed |
| CN-104363894-A | Vesicular formulations for use in the treatment of pain or reduced mobility of a joint | SEQUESSOME TECHNOLOGY HOLDINGS LTD | 2015-02-18 | — | — | CN | disclosed |
| CN-104349782-A | Vesicular formulations | SEQUESSOME TECHNOLOGY HOLDINGS LTD | 2015-02-11 | — | — | CN | disclosed |
| CN-102770162-A | Vesicular formulations | TARGETED DELIVERY TECHNOLOGIES LTD | 2012-11-07 | — | — | CN | disclosed |
| CN-102639113-A | Preparation for treating deep tissue pain | CHARLES MAYO JOHN | 2012-08-15 | — | — | CN | disclosed |
| CN-101862295-A | Aggregate having enhanced deformability and including at least three amphipatic substances | IDEA AG | 2010-10-20 | — | — | CN | disclosed |
| CN-1703199-B | Aggregate with enhanced deformability comprising at least three amphiphiles for improved transport through a semi-permeable barrier and use of non-invasive drugs in vivo, in particular through the skin | IDEA AG | 2010-04-28 | — | — | CN | disclosed |
| CN-1703199-A | Aggregate with enhanced deformability comprising at least three amphiphiles for improved transport through a semi-permeable barrier and use of non-invasive drugs in vivo, in particular through the skin | IDEA AG (DE) | 2005-11-30 | — | — | CN | disclosed |
| US-20020173489-A1 | COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS | MAX-PLANCK-GESSELSCHAFT ZUR FORDERUNG DER WISSENSCHAFTER E.V. (DE) | 2002-11-21 | — | — | US | disclosed |
| US-5916884-A | CYTOTOXIC THERAPEUTIC COMPOUND; ANTITUMOR AGENT | MAX-PLANCK-GESELLSCHAFT ZUR FOEDERUNG DER WISSENSCHAFTEN (DE) | 1999-06-29 | — | — | US | disclosed |
| EP-0248062-B1 | MEDICAMENTS | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1992-05-06 | — | — | EP | disclosed |
| EP-0225608-A2 | Medicine | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1987-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173489-A1 | COMPOSITIONS CONTAINING A MIXTURE OF PHOSPHOROUS COMPOUNDS AND ALKYLGLYCEROLS | PHOSPHO1, PLCG2, PPIP5K2 | FDPS 668/4885GGPS1 105/4885SMPD1 77/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.